IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** Serial No.

Simons et al.

Flied

09/145,916 September 2, 1998

For

"STIMULATION OF ANGIOGENESIS VIA

ENHANCED ENDOTHELIAL EXPRESSION

OF SYNDECAN-4 CORE PROTEINS"

Examiner

David Guzo

Group Art Unit

1636

Attorney's Docket No. **BIS-039** 

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

on:\_

Attorney for Applicants >

Signature:

Date:

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures as mailed October 10, 2001 and extended through February 10, 2002, please find enclosed the following

documents for filing on behalf of applicants and for formal entry into the above-identified application:

- A Second Amendment Of Specification And Request For Entry Of A Second Paper Form Copy Of The Sequence Listing Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures.
- 2. A replacement amended paragraph page for the Specification.
- 3. A second paper form copy of the "Sequence Listing" to be formally entered into the original Specification of the aboveidentified patent application.
- 4. A marked-up copy of the replacement amended paragraph page for the Specification pursuant to 37 C.F.R. 121(b).
- 5. A second computer readable form (CRF) copy of the "Sequence Listing".
- 6. A Second Statement And Verification Of Substantive Identity

  Between The Second Computer Readable Form (CRF) Copy And

  The Second Paper Form Copy Of The "Sequence Listing".
- One copy of the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures as mailed October 10, 2001.

Respectfully submitted,

SIMONS et al.

Magnolia, Massachusetts 01930

Tel.: (978) 525-3794

David Prashker

Reg. No. 29,693

Attorney for applicants

02; 9:56

SLOUCESTER CO-OPERATIVE BANK #BE 2 0 2 E # 1 2 % 0060 1.90

Applicants' Copy

Application No.

09/145916

MOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING MUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

th nucleotide and/or amino acid sequenc disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 -1.825 for the following reason(s): 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OC 29. May 15, 1990 and at 55 FR 18230, May 1, 1990. 2. This application does not contain, as a separate part of the disclosure on pap r copy, a "Sequence Listing" as required by 37 CFR 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing. " 5. The computer readable form that has been filed with this application has be n found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Amino acid sequence on Page 29 missing from Sequence In Applicant must provide: An initial or substitute computer readable form (CRF) copy of the "Sequence List/Ing" An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) For questions regarding compliance with these requirements, please contact: For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212

For PatentIn software h lp, call (703) 557-0400